Market Expansion and Commercial Outlook“Demand for Rezdiffra remains strong,” Chief Executive Officer Bill Sibold said during the company’s earnings call. Madrigal said the U.S. addressable market for diagnosed F2/F3 MASH patients treated by its target specialists grew to approximately 460,000 patients at the end of 2025, compared with 315,000 at the end of 2023. Selling, general and administrative expense increased to $289.4 million from $196.9 million, reflecting commercial investment in Rezdiffra, including the endocrinology field-force expansion and direct-to-consumer marketing. Sibold said Madrigal recently received three additional patents related to Rezdiffra, including two patents supporting protection in F2-F3 MASH and one supporting a potential F4C indication. About Madrigal Pharmaceuticals (NASDAQ:MDGL)Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases.